Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011
DateTitle 
December 21, 2011BioTime Signs Agreement with USCN Life Science to Source Antibody-Based Products
ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 21, 2011-- BioTime, Inc. (NYSE Amex: BTX) today announced agreements with USCN Life Science, Inc. (USCN) of Wuhan, China, granting BioTime an option to license USCN’s antibody-producing cell lines and certain related technology that may be used by BioTime and its subsidiary OncoCyte Corporation for the large-scale manufacture of the antibody components of PanC-DxTM. PanC-DxTM is a novel diagnostic technol... 
Printer Friendly Version
December 16, 2011BioTime's Subsidiary OncoCyte Corporation Announces Plans for the Novel Pan-Cancer Diagnostic Product PanC-DxTM
- A novel blood-based screening method for the early detection of many common human cancers such as those of the breast, colon, and lung - ALAMEDA, Calif., Dec 16, 2011 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTX) and BioTime's subsidiary OncoCyte Corporation today announced plans for the development of PanC-DxTM, a novel diagnostic device discovered at BioTime and OncoCyte to detect the presence of various human cancers, including cancers of the br... 
Printer Friendly Version
August 24, 2011BioTime's Subsidiary OncoCyte Corporation Expands Cancer Programs with $10 Million Equity Financing
Capital to be utilized in advancing the development of novel cancer diagnostic and therapeutic products BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced its majority-owned subsidiary OncoCyte Corporation (OncoCyte) has received a new round of equity financing to fund expansion of its development of novel proprietary diagnostics and therapeutics for cancer in humans. The financing included... 
Printer Friendly Version
April 05, 2011BioTime and XenneX Form LifeMap Sciences, Inc. to Create Roadmap for Regenerative Medicine
Database to promote the marketing of BioTime's research products BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced it has formed LifeMap Sciences, Inc., in collaboration with XenneX, Inc. LifeMap Sciences will develop and commercialize a database of the thousands of cell lineages branching from embryonic stem cells, and their molecular markers. LifeMap Sciences plans to make ... 
Printer Friendly Version
March 22, 2011BioTime Announces the Closing of the Merger of Glycosan BioSystems with OrthoCyte Corporation
William P. Tew, Ph.D. Becomes Vice President, Business Development of BioTime and OrthoCyte BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the fields of stem cells, regenerative medicine and blood plasma volume expanders today announced it has completed the merger of Glycosan BioSystems, Inc. into BioTime's wholly-owned subsidiary OrthoCyte Corporation. The definitive merger agreement was previously announced on February 14, 2011. OrthoCyt... 
Printer Friendly Version
February 14, 2011BioTime Announces Agreement To Acquire Glycosan BioSystems
Acquisition to accelerate BioTime's development of tissue engineered therapeutic products and expand research product portfolio BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced it has signed a definitive agreement to merge Utah-based Glycosan BioSystems, Inc. (Glycosan) with BioTime's wholly-owned subsidiary, OrthoCyte Corporation. The acquisition is expected to close by March ... 
Printer Friendly Version
January 28, 2011BioTime Acquires Assets of Cell Targeting, Inc.
--Proprietary technology "paints" cells with peptides to target them to diseased tissues-- BioTime, Inc. (NYSE Amex:BTX) today announced that it has acquired substantially all the assets of Cell Targeting, Inc. (CTI), a Cleveland, Ohio-based biotechnology company conducting research in regenerative medicine. The technology acquired from CTI uses peptides selected for their ability to adhere to diseased tissues. By coating or "painting" these peptides onto the surfaces of therapeutic cel... 
Printer Friendly Version
January 03, 2011BioTime Subsidiary ReCyte Therapeutics, Inc. to Develop Therapies for Age-Related Cardiovascular and Blood Disorders
$4 Million Equity Financing Company Plans Near-Term Commercialization of iPS Cell Banking Services that Reverse the Developmental Aging of Human Cells BioTime, Inc. (NYSE Amex:BTX) today announced a $4 million equity financing by its subsidiary, Embryome Sciences, Inc. Concurrent with the financing, Embryome Sciences will be renamed ReCyte Therapeutics, Inc. and will develop therapeutic products for cardiovascular and blood diseases. The new equity financing is being led by a $2.5 mill... 
Printer Friendly Version